spacer
home > ebr > spring 2003 > robotics in pharmaceutical research
PUBLICATIONS
European Biopharmaceutical Review

Robotics in Pharmaceutical Research

'Robot' is a Czech word meaning worker, from the play RUR: Rossums' Universal Robots by the Bohemian writer Karel Capek. The robot has since become an inspiration for science fiction writers and for engineers. Of course the science fiction vision of a robot is a mechanical man, but the reality we see in industry is simply a robotic arm. This is a versatile programmable manipulator, an integration of mechanics, electronics and software, designed interdependently to produce the mechanical equivalent of the computer - an undedicated machine unable to do anything until we program it.

In the pharmaceutical lab it is even less than that definition; the term 'robot' being applied to programmable liquid handlers. Drug development requires the screening of hundreds or thousands of samples and it is in this field that the robot arm is a vital tool. Such an automated screening system is called a 'high-throughput screening' (HTS) system.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
By David N Sands, CEO and Founder of ST Robotics International

David N Sands was educated in London. He founded Sands-Whiteley Research and Development, which concentrated on advanced electronics and industrial automation using mini-computers and later microprocessors. David was a Department of Industry Consultant on microprocessors for many years. In 1982 the first robots were designed and Cyber Robotics, which was later sold to the Bibby Corporation, was formed the same year.

David wrote the first robot software, ROBOFORTH, in 1982 and designed the first robot controller in 1985. In 1989 he formed Sands Technology with Catherine George and ST-Monforte Robotics with Mathew Monforte in Trenton, New Jersey, in 1991. Sands Technology International Inc was formed in 1992 with Mathew Monforte as Vice President.
 

spacer
David N Sands
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Saneca to drive R&D Initiative following 1.5 million funding


More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

Drug Discovery 2018

21-22 March 2018, Copthorne Tara Hotel, Scarsdale Place, Kensington, London

SMi Group is proud to announce the return of Drug Discovery in 2018. The successful conference will return for its 2nd year on the 21st and 22nd March.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement